Biodexa Pharmaceuticals Plc ADR (BDRX)

$3.13 -0.02 (-0.63%)
Market Cap 6.29M
Revenue (ttm) 0.00
Net Income (ttm) -8.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 15,400
Avg Vol 925,254
Day's Range N/A - N/A
Shares Out 2.00M
Stochastic %K 4%
Beta 1.15
Analysts Strong Buy
Price Target $35.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
luckyluke17
luckyluke17 May. 19 at 1:49 PM
$BDRX buying more here
0 · Reply
CoffeeRocks
CoffeeRocks May. 19 at 1:21 PM
$CODX $APUS $BTAI CODX running $BDRX
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx May. 19 at 3:42 AM
$BDRX last man standing Dr
1 · Reply
zsk78
zsk78 May. 15 at 3:39 PM
$BDRX 3.06 🧐
1 · Reply
luckyluke17
luckyluke17 May. 14 at 3:18 PM
$BDRX with CTB up over 500% if you've shorted in this range it's costing about $500 a day for a 10K short position. 180K if you hold for the year (at 500% CTB)
1 · Reply
luckyluke17
luckyluke17 May. 14 at 2:20 PM
$BDRX is reducing the number of ordinary shares. Vote at the AGM in June. Guessing this is the first of the three updates @Love_To_Learn knows about
0 · Reply
luckyluke17
luckyluke17 May. 12 at 2:10 PM
$BDRX 41K shorts down to an apparent 17K on the official SI report released yesterday. That is as of April 30th settlement date. But CTB up in the upper 400, low 500% (still climbing), borrow availability is still scarce and let's not forget the 906K short volume on May 5th (after the last reported settlement date). Imo short numbers still getting figured out, nevertheless boom boom candles incoming.
0 · Reply
luckyluke17
luckyluke17 May. 12 at 12:53 PM
$BDRX @Love_To_Learn would love a Beud update, even if not tagged directly. No posts on Beud in weeks means you want it quiet here for now I'm guessing
0 · Reply
luckyluke17
luckyluke17 May. 11 at 9:44 PM
$BDRX dipping into the underwear money fund on this dip 😉
0 · Reply
stockobserver
stockobserver May. 11 at 8:03 PM
$BDRX Wants low 3
1 · Reply
Latest News on BDRX
Biodexa issues letter to Shareholders

May 14, 2026, 8:30 AM EDT - 5 days ago

Biodexa issues letter to Shareholders

Biodexa Pharmaceuticals PLC-ADR trading halted, news pending

2026-04-02T23:50:17.000Z - 6 weeks ago

Biodexa Pharmaceuticals PLC-ADR trading halted, news pending

Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene

2026-04-02T13:12:12.000Z - 6 weeks ago

Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Apr 2, 2026, 8:30 AM EDT - 6 weeks ago

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Biodexa, Tanner Pharma launch global early access program for FAP patients

2026-03-31T12:47:27.000Z - 7 weeks ago

Biodexa, Tanner Pharma launch global early access program for FAP patients

Preliminary Results for the Year Ended 31 December 2025

Mar 27, 2026, 5:00 PM EDT - 7 weeks ago

Preliminary Results for the Year Ended 31 December 2025

Biodexa Pharmaceuticals management to meet with Maxim

2026-03-23T14:45:08.000Z - 2 months ago

Biodexa Pharmaceuticals management to meet with Maxim

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

Mar 23, 2026, 8:30 AM EDT - 2 months ago

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

Biodexa Pharmaceuticals announces one-for-five reverse ADR split

2026-03-18T21:10:28.000Z - 2 months ago

Biodexa Pharmaceuticals announces one-for-five reverse ADR split

ADR Ratio Change

Mar 18, 2026, 5:00 PM EDT - 2 months ago

ADR Ratio Change

Biodexa Pharmaceuticals supports Life’s a Polyp Foundation

2026-03-09T12:40:09.000Z - 2 months ago

Biodexa Pharmaceuticals supports Life’s a Polyp Foundation

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Mar 9, 2026, 8:30 AM EDT - 2 months ago

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Feb 19, 2026, 7:30 AM EST - 3 months ago

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical

2026-02-04T13:36:46.000Z - 3 months ago

Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Feb 4, 2026, 8:30 AM EST - 3 months ago

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary

2026-01-05T13:41:08.000Z - 4 months ago

Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Jan 5, 2026, 8:30 AM EST - 4 months ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering

2025-12-18T13:35:26.000Z - 5 months ago

Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering

Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 5 months ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Pharmaceuticals PLC-ADR trading resumes

2025-12-08T14:41:04.000Z - 5 months ago

Biodexa Pharmaceuticals PLC-ADR trading resumes

Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause

2025-12-08T14:35:30.000Z - 5 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause

Biodexa announces enrollment of first European patients in Phase 3 Serenta trial

2025-12-01T13:35:58.000Z - 6 months ago

Biodexa announces enrollment of first European patients in Phase 3 Serenta trial

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 6 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial

2025-11-24T13:45:58.000Z - 6 months ago

Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 6 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Pharmaceuticals files to sell 3.38M units

2025-11-17T22:05:23.000Z - 6 months ago

Biodexa Pharmaceuticals files to sell 3.38M units

Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP

2025-11-03T13:35:20.000Z - 7 months ago

Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 7 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 8 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Biodexa Pharmaceuticals files $100M mixed securities shelf

2025-09-26T21:05:13.000Z - 8 months ago

Biodexa Pharmaceuticals files $100M mixed securities shelf

Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year

2025-09-12T12:35:32.000Z - 8 months ago

Biodexa Pharmaceuticals reports 1H EPS (GBP0.0002) vs. (GBP0.001) last year

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 8 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 9 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa announces enrollment of first two patients in Phase 3 Serenta trial

2025-08-18T12:35:17.000Z - 9 months ago

Biodexa announces enrollment of first two patients in Phase 3 Serenta trial

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 9 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 10 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 10 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 11 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 11 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 11 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 11 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 1 year ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 1 year ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 1 year ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 1 year ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 1 year ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

luckyluke17
luckyluke17 May. 19 at 1:49 PM
$BDRX buying more here
0 · Reply
CoffeeRocks
CoffeeRocks May. 19 at 1:21 PM
$CODX $APUS $BTAI CODX running $BDRX
0 · Reply
zzzzzzzzzzzxxx
zzzzzzzzzzzxxx May. 19 at 3:42 AM
$BDRX last man standing Dr
1 · Reply
zsk78
zsk78 May. 15 at 3:39 PM
$BDRX 3.06 🧐
1 · Reply
luckyluke17
luckyluke17 May. 14 at 3:18 PM
$BDRX with CTB up over 500% if you've shorted in this range it's costing about $500 a day for a 10K short position. 180K if you hold for the year (at 500% CTB)
1 · Reply
luckyluke17
luckyluke17 May. 14 at 2:20 PM
$BDRX is reducing the number of ordinary shares. Vote at the AGM in June. Guessing this is the first of the three updates @Love_To_Learn knows about
0 · Reply
luckyluke17
luckyluke17 May. 12 at 2:10 PM
$BDRX 41K shorts down to an apparent 17K on the official SI report released yesterday. That is as of April 30th settlement date. But CTB up in the upper 400, low 500% (still climbing), borrow availability is still scarce and let's not forget the 906K short volume on May 5th (after the last reported settlement date). Imo short numbers still getting figured out, nevertheless boom boom candles incoming.
0 · Reply
luckyluke17
luckyluke17 May. 12 at 12:53 PM
$BDRX @Love_To_Learn would love a Beud update, even if not tagged directly. No posts on Beud in weeks means you want it quiet here for now I'm guessing
0 · Reply
luckyluke17
luckyluke17 May. 11 at 9:44 PM
$BDRX dipping into the underwear money fund on this dip 😉
0 · Reply
stockobserver
stockobserver May. 11 at 8:03 PM
$BDRX Wants low 3
1 · Reply
luckyluke17
luckyluke17 May. 11 at 7:11 PM
$BDRX buying more here.
0 · Reply
zsk78
zsk78 May. 9 at 1:13 PM
$BDRX going to get volatile soon, got some time to look through this.. might even be next week but first impulse move otw. Would expect massive fireworks by mid-june on later end. New alerts set
1 · Reply
luckyluke17
luckyluke17 May. 9 at 12:14 AM
$BDRX lives will be changed here the next month, stay cool calm and collected. Have a good weekend everybody.
0 · Reply
TheRipple
TheRipple May. 8 at 4:25 PM
$BDRX
0 · Reply
luckyluke17
luckyluke17 May. 7 at 9:25 PM
$BDRX
0 · Reply
luckywabbit
luckywabbit May. 7 at 8:36 PM
$BDRX https://www.facebook.com/share/v/1CL69LVHMn/
1 · Reply
Yourmom198
Yourmom198 May. 7 at 7:46 PM
$BDRX don’t chase, now is the time to buy.
1 · Reply
Stoksgeek
Stoksgeek May. 7 at 1:51 PM
$BDRX strong
0 · Reply
luckyluke17
luckyluke17 May. 6 at 7:21 PM
$BDRX
0 · Reply
luckyluke17
luckyluke17 May. 6 at 4:35 PM
$BDRX @Love_To_Learn from 3.37 to that 4.42 range. Release the update and we run!
2 · Reply
luckyluke17
luckyluke17 May. 6 at 4:20 PM
$BDRX still 0 shares available to borrow since 10:44am yesterday. Last 3 weeks the cost to borrow has been over 200%. It's costing shorts a couple grand a day to hold
0 · Reply
Game_Day
Game_Day May. 6 at 1:37 PM
PASS 🏆 $ABBV $BDRX $CABA $PAAS
0 · Reply